Switching From Tirzepatide or Semaglutide to Retatrutide: The Complete Protocol

Switching to retatrutide from tirzepatide or semaglutide is the most common transition question in GLP-1 research right now, and the published data answers most of it. The short version: there is no milligram conversion between these compounds, every switch restarts at retatrutide’s lowest dose regardless of prior dose, and the transition window is one dosing interval. The longer version — why those rules hold, what the plateau data shows, and how the first four weeks should be structured — is below.

This guide covers the three molecules’ receptor profiles and half-lives, the reason dose-matching fails, a washout and week-1 protocol drawn from trial design, and what to expect from a plateau after a single- or dual-agonist course. All dose figures come from the published trials cited; nothing here is a clinical recommendation.

Why Researchers Switch: The Plateau Problem

The most common reason for a switch is a plateau. Semaglutide’s STEP 1 trial showed weight loss flattening at roughly week 60, with a mean of 14.9% at 68 weeks. Tirzepatide’s SURMOUNT-1 reached 22.5% at 72 weeks with the curve still declining but slowing. Retatrutide’s TRIUMPH-1 reached 28.3% at 80 weeks and — in the BMI ≥35 extension — 30.3% at 104 weeks, with Lilly stating the curve had not plateaued (Lilly, TRIUMPH-1 topline, May 21, 2026).

The mechanistic explanation for why a triple agonist keeps going where a single agonist stalls is the glucagon receptor. GLP-1 and GIP agonism reduce intake. Glucagon agonism increases hepatic lipid oxidation and energy expenditure. A single-agonist plateau reflects the body’s adaptive reduction in resting energy expenditure catching up with reduced intake; adding an expenditure-side mechanism shifts that equilibrium. This is the pharmacological rationale, not a guarantee — individual response varies and TRIUMPH-5, the head-to-head against tirzepatide, has not reported.

The second reason is cost per milligram. A 12 mg retatrutide dose is the trial maximum; a 15 mg tirzepatide dose is its maximum. Research vial pricing per milligram is comparable, but the retatrutide maintenance question — Lilly has flagged the 4 mg dose as producing 19% loss with lower discontinuation — may mean lower long-run consumption. That data is preliminary.

The Three Molecules Compared

Sources: Wilding et al., NEJM 2021 (STEP 1); Jastreboff et al., NEJM 2022 (SURMOUNT-1); Lilly TRIUMPH-1 topline; Jastreboff et al., NEJM 2023 (retatrutide Phase 2, escalation schedule).

Why There Is No Dose Conversion

The instinct to map doses — “I was on 15 mg tirzepatide, so I should start retatrutide at 12 mg” — is the most common switching error, and the reason it fails is structural.

Milligram figures across these compounds are not comparable because each drug’s dose range was set independently to its own receptor profile. Semaglutide’s 2.4 mg ceiling and retatrutide’s 12 mg ceiling are not “five times more drug” in any meaningful sense; they are each the dose at which that molecule’s specific receptor activation produces its studied effect. A 2 mg retatrutide start is not “eight times” a 0.25 mg semaglutide start.

More importantly, glucagon-receptor agonism is new to anyone switching from semaglutide or tirzepatide. GI tolerance built on GLP-1 stimulation does not transfer to the glucagon component, and the dysesthesia signal — 8.8% at 9 mg and 20.9% at 12 mg in TRIUMPH-4, versus 0.7% placebo — is dose-dependent and glucagon-linked. Starting at a high retatrutide dose to “match” a prior tirzepatide dose skips the tolerance-building that the four-week escalation exists to provide.

The published trials all started retatrutide at 2 mg regardless of prior exposure. That is the only evidence-supported starting point.

The Washout Question

Washout is the gap between the last dose of the outgoing compound and the first dose of retatrutide. The purpose is to avoid stacking two GLP-1 agonists during the overlap period, which compounds GI effects without adding benefit.

All three drugs are once-weekly with half-lives of 5–7 days, which means a single dosing interval is the natural washout. The protocol that follows from the pharmacokinetics: take the last dose of semaglutide or tirzepatide on schedule, skip nothing, and begin retatrutide at 2 mg on the day the next dose of the outgoing compound would have been due. At that point roughly half of the outgoing drug remains in circulation — enough to prevent a full rebound in appetite, not enough to double up meaningfully with a 2 mg retatrutide start.

A longer washout — two weeks — reduces overlap further but allows appetite to return fully in the gap. A shorter washout, or same-day switching, stacks two agonists at meaningful concentrations and is the pattern most associated with severe nausea reports. One interval is the compromise the pharmacology supports.

Week-by-Week Transition Protocol

The escalation is the TRIUMPH-1 schedule exactly. Two points from the trial design matter for a switch: escalation was allowed to stall at any step if tolerance required it, and the 4 mg and 9 mg arms both met primary endpoints — the 12 mg maximum is not a target, it is a ceiling.

Weight-loss expectations in weeks 1–4 should be modest. The outgoing compound’s effect is fading and retatrutide at 2 mg is sub-therapeutic by trial standards. Researchers who expect the switch to produce an immediate acceleration are usually measuring during the one window where it cannot.

What the Plateau Data Actually Shows

Three things about plateaus are established in the literature, and one is not.

Established: weight loss on any GLP-1 class drug slows and then stops at a new equilibrium. For semaglutide that equilibrium arrived around week 60 in STEP 1. For tirzepatide it was approaching at week 72 in SURMOUNT-1. The mechanism is adaptive thermogenesis — resting energy expenditure falls as weight falls, until it matches the reduced intake.

Established: lean mass loss accompanies fat loss on all of these drugs, at roughly 25–40% of total weight lost in published body-composition substudies. Lean mass loss reduces resting energy expenditure further, accelerating the plateau. Resistance training and protein intake are the standard mitigations in every trial protocol.

Established: retatrutide’s curve had not plateaued at 80 weeks in TRIUMPH-1 or at 104 weeks in the BMI ≥35 extension. This is the primary evidence that the triple agonist reaches a lower equilibrium than the single or dual agonists.

Not established: whether switching to retatrutide after a plateau on tirzepatide restarts loss to the same degree as starting retatrutide fresh. TRIUMPH-5, the head-to-head, will report from 2027. No published trial has enrolled participants at a prior-drug plateau. The mechanistic case is strong; the direct evidence does not exist yet.

Where Cagrilintide Fits

An alternative to switching compounds is adding a mechanism. Cagrilintide is a long-acting amylin analog — a fourth pathway, independent of GLP-1, GIP, and glucagon — and Novo’s CagriSema trials showed that adding cagrilintide 2.4 mg to semaglutide 2.4 mg raised 68-week loss from 16.1% to 22.7% in REDEFINE-1 (Garvey et al., NEJM 2025). Whether the same additive effect holds with retatrutide has not been studied; the pharmacological logic is that amylin receptor agonism is orthogonal to all three of retatrutide’s targets.

For a plateau on tirzepatide or semaglutide, the two research options are therefore: switch to retatrutide (adds glucagon), or add cagrilintide (adds amylin). The switching protocol above covers the first. The cagrilintide stacking guide covers the second.

Sourcing Notes

PSPeptides carries retatrutide in 10, 15, 20, 30, 40, 50, and 60 mg lyophilized vials, each with a lot-specific HPLC certificate of analysis. For a research course following the TRIUMPH escalation, the 10 mg and 20 mg sizes cover weeks 1–8 (2 mg and 4 mg weekly); larger vials become efficient from the 9 mg step. Reconstitution uses bacteriostatic water; the reconstitution calculator handles the volume and syringe-unit math for each vial size.

Frequently Asked Questions

How long should I wait between my last tirzepatide dose and first retatrutide dose?

One dosing interval — seven days. Take the final tirzepatide dose on schedule, then begin retatrutide at 2 mg on the day the next tirzepatide dose would have fallen. This leaves roughly half the tirzepatide in circulation, which prevents full appetite rebound without meaningfully stacking two agonists at a 2 mg retatrutide start.

Can I start retatrutide at a higher dose if I was on high-dose tirzepatide?

The published trials all started at 2 mg regardless of prior GLP-1 exposure, and the reason is the glucagon component — it is new to anyone coming from tirzepatide or semaglutide, and GI tolerance built on GLP-1/GIP does not transfer to it. The dysesthesia signal is also dose-dependent. Starting high to “match” a prior dose skips the tolerance the four-week escalation exists to build.

Will switching to retatrutide break my tirzepatide plateau?

The mechanistic case is that glucagon agonism adds an energy-expenditure pathway that single and dual agonists lack, and retatrutide’s own trial curve had not plateaued at 104 weeks. But no published trial has enrolled participants at a prior-drug plateau — TRIUMPH-5 (vs tirzepatide) reports from 2027. The rationale is strong; the direct evidence is pending.

Is retatrutide approved?

No. It is investigational. Lilly plans to file a BLA in Q1 2027 with an FDA decision plausible in late 2027 (priority review) or 2028 (standard). Semaglutide and tirzepatide are approved medications; retatrutide is available only as a research compound.

All PSPeptides products are sold exclusively for research and laboratory use.